REGN's melanoma combo misses the primary endpoint in a phase III study despite longer median PFS versus Keytruda monotherapy.
Jennifer Frederick was in the best shape of her life in 2023, so when she felt a small lump in her groin area after a week of workouts. She thought it was just a pulled muscle, but a month later, the ...
Aulos Bioscience, a clinical-stage immuno-oncology company developing an immune-activating antibody therapeutic designed by leveraging an AI platform, today announced positive Phase 2 data from its ...
Melanoma is among the most preventable skin cancers when found early, yet it remains the skin cancer most likely to spread ...
MarketBeat Week in Review – 7/15 - 7/19 IDEAYA Biosciences (NASDAQ:IDYA) said its lead oncology program remains on track for ...
Dermatomyositis is an autoimmune inflammatory muscle disease that is linked to cancer in approximately one third of the cases. The most commonly associated cancers are ovarian, lung, gastric, ...
Regeneron’s phase 3 trial of the LAG-3 inhibitor fianlimab plus cemiplimab failed to meet its primary endpoint of progression-free survival in first-line advanced melanoma.
Obesity is known to increase the risk of developing many different types of cancer. It’s also associated with worse outcomes in several cancers but improved outcomes in others (in what has been dubbed ...
Dermatology Nursing. 2005;17(3):188-190. A 45-year-old woman presented with a rapidly changing nevus on her leg. The clinical approach, epidemiology, diagnostic procedures, and management, along with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results